Reply to thread

Message: [QUOTE="greenmedinfo, post: 5493"] PMID: Cardiovasc Hematol Disord Drug Targets. 2021 Dec 14. Epub 2021 Dec 14. PMID: 34906063 Abstract Title: Vitamin C inhibits Angiotensin-Converting Enzyme-2 in Isolated Rat Aortic Ring. Abstract: AIMS: The study aimed to assess the inhibitory effect of Vitamin C on angiotensin-converting enzyme 2.BACKGROUND: Coronavirus disease 2019 (COVID-19) is a disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which uses angiotensin-converting enzyme 2 (ACE-II) as the first route to infect human cells. Accordingly, agents with potential inhibition of ACE-II receptors might be effective in the prevention and management of COVID-19.OBJECTIVE: The goal of this work was to assess the possible inhibitory effect of ACE-II on ascorbic acid using an ex vivo approach based on the inhibition of diminazene-induced vasorelaxation.MATERIAL AND METHODS: In the present study, diminazene was used as a known specific inhibitor of ACE-II. Then, the vasorelaxant effect of ascorbic acid on diminazene-induced relaxation was examined using isolated aortic rings. All experiments of this study were evaluated on isolated aortic rings precontracted by epinephrine.RESULTS: The results confirmed that diminazene-induced vasorelaxation in a dose-dependent manner. More interestingly, ascorbic acid inhibited diminazene-induced vasorelaxation in a dose-dependent manner.CONCLUSION: This investigation provides valuable experimental proof of the efficacy of ascorbic acid (Vitamin C) on inhibiting ex vivo vascular angiotensin-converting enzyme II, which is known among the pharmacological targets of anti-Covid-19 drugs. [URL='https://www.greenmedinfo.com/article/vitamin-c-inhibits-angiotensin-converting-enzyme-2-isolated-rat-aortic-ring']read more[/URL] [/QUOTE]

Verification

Top Bottom

Search

Search

Reply to thread